Improved GPCR ligands from nanobody tethering

Antibodies conjugated to bioactive compounds allow targeted delivery of therapeutics to cell types of choice based on that antibody’s specificity. Here we develop a new type of conjugate that consists of a nanobody and a peptidic ligand for a G protein-coupled receptor (GPCR), fused via their C-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheloha, Ross W., Fischer, Fabian A., Woodham, Andrew W., Daley, Eileen, Suminski, Naomi, Gardella, Thomas J., Ploegh, Hidde L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190724/
https://www.ncbi.nlm.nih.gov/pubmed/32350260
http://dx.doi.org/10.1038/s41467-020-15884-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190724/
https://www.ncbi.nlm.nih.gov/pubmed/32350260
http://dx.doi.org/10.1038/s41467-020-15884-8

Ejemplares similares